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ABSTRACT The effect of the nicotinic agonist AG-4 on memory processes was evaluated in the mouse
passive avoidance test. AG-4 (100 m g per mouse icv) prevented amnesia induced by scopolamine (1.5 mg
kg–1 ip), mecamylamine (20 mg kg–1 ip), and dihydro- b -erythroidine (10 m g per mouse icv). In the same
experimental conditions, AG-4 (100 m g per mouse icv) also prevented baclofen (2 mg kg–1 ip), clonidine
(0.125 mg kg–1 ip), and diphenhydramine (20 mg kg–1 ip) amnesia in mice. AG-4 exerted an antiamnesic
effect comparable to that produced by nicotine (2 mg kg–1 ip), physostigmine (0.2 mg kg–1 ip), and the
nootropic drug piracetam (30 mg kg–1 ip). At the active dose, AG-4 did not impair mice motor coordina-
tion and spontaneous motility as revealed, respectively, by Rota-rod test and Animex apparatus. Present
results evidence the antiamnesic activity of the nicotinic agonist AG-4 suggesting a potential employment
of this compound in the symptomatic treatment of cognitive impairments.  Drug Dev. Res. 51:191–196,
2000. © 2001 Wiley-Liss, Inc.
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INTRODUCTION
Nicotine enhances cognitive function in normal rats
[Levine et al., 1990; Levin, 1992] and attenuates memory
deficits produced by destruction of cholinergic input to
the cortex and hippocampus [Tilson et al., 1988; Decker
et al., 1992; Hodges et al., 1992], an effect shared by some
other nicotinic acetylcholine receptor (nAChR) agonists
[Decker et al., 1993]. In addition, nicotine improves short-
term memory performance in both young and aged mon-
keys [Elrod et al., 1988; Buccafusco and Jackson, 1991].
The involvement of nicotinic neurotransmission in cog-
nitive function processes is further substantiated by ob-
served deficits in cognitive performances following
administration of mecamylamine, an nAChR channel
blocker, to rodents [Oliverio, 1966; Levine et al., 1987;
Riekkinen et al., 1990], monkeys [Elrod et al., 1988], and
humans [Newhouse et al., 1992]. Strong evidence for the
potential of central nicotinic stimulation to enhance cog-
nitive performance in Alzheimer disease patients derives
from the clinical observation that nicotine infused intra-
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venously significantly reduced the number of errors in
cognitive tests [Newhouse et al., 1988].
The beneficial effect of nicotine was also observed
with other agents that act at nAChRs. (-)-Lobeline
[Decker et al., 1993] and ABT-418 [Decker et al., 1994]
have both been reported to ameliorate spatial learning
deficits in rats with septal lesions. Similarly, GTS-21 im-
proved avoidance learning in rats with nucleus basalis
magnocellularis lesions and reduced age-related learn-
ing deficits in both rats and rabbits [Arendash et al., 1995;
Woodruff-Pak et al., 1994]; DBO-83 also prevented phar-
macological-induced amnesia in the passive avoidance
test [Ghelardini et al., 1998].
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The compound AG-4 (2-methyl-5-N,N-dimethyl-
aminomethyl-cyclopentan-1-one methyl iodide) has been
reported by Giannella et al. [1980] to be an agonist selec-
tive for the nicotinic receptors. It has also been reported
that AG-4 enhanced the pain threshold in rodents with-
out eliciting any side effect [Ghelardini et al., 1997].
Within the framework of research for new nicotinic ago-
nists acting as cognitive enhancers, it was decided to in-
vestigate the pharmacological profile of AG-4 as a
compound endowed with antiamnesic properties. In or-
der to delineate the AG-4 procognitive action, its poten-
tial antiamnesic activity was investigated in the mouse
passive avoidance test.
MATERIALS AND METHODS
Animals
Male Swiss albino mice (24–26 g) from Morini (San
Polo d’Enza, Italy) were used. Fifteen mice were housed
per cage. The cages were placed in the experimental
room 24 h before the test for acclimatization. The ani-
mals were fed a standard laboratory diet and tap water
ad libitum and kept at 23 –  1 ° C on a 12-h light/dark cycle,
lights on at 7AM.
Passive Avoidance
The test was performed according to the step-
through method described by Jarvik and Kopp [1967]. The
apparatus consists of a two-compartment acrylic box with
a lighted compartment connected to a darkened one by a
guillotine door. As soon as mice entered the dark com-
partment they received a punishing electrical shock (0.15
mA, 1 sec). The latency times for entering the dark com-
partment were measured in the training test and after 24
h in the retention test. The maximum entry latency allowed
in the training and retention session was 60 and 180 sec,
respectively. The memory degree of received punishment
was expressed as increase in seconds between the laten-
cies recorded in the training and retention sessions.
Rota-Rod Test
The apparatus consisted of a base platform and a
rotating rod of 3 cm diameter with a nonslippery surface.
This rod was placed at a height of 15 cm from the base.
The rod, 30 cm in length, was divided into five equal
sections by six disks. Thus, up to five mice were tested
simultaneously on the apparatus, with a rod-rotating
speed of 16 rpm. The integrity of motor coordination was
assessed according to Kuribara et al. [1977] on the basis
of endurance time of the animals on the rotating rod. One
day before the test the animals were trained twice. On
the day of the test only the mice that were able to stay
balanced on the rotating rod between 70 and 120 sec (cut-
off time) were selected for testing. The performance time
was measured before and at various times after treatment.
Spontaneous Activity Meter (Animex)
Locomotor activity in mice was quantified using an
Animex activity meter Type S (LKB, Farad, Sweden) set to
maximum sensitivity. Every movement of mice, which
were placed on top of the Animex activity meter, produced
a signal due to variation in inductance and capacity of the
apparatus resonance circuit. Then signals were automati-
cally converted to numbers. On the day of the experiment
the mice were treated and then the cage, containing five
mice, was put on the measuring platform. Activity counts
were made every 15 min for 45 min starting immediately
after injection of the drug. Because of the arbitrary scale
adopted to quantify movements, drug-treated mice were
always compared with saline-treated ones.
ICV Injection Technique
Intracerebroventricular (icv) administration was per-
formed under ether anesthesia with isotonic saline as sol-
vent, according to the method described by Haley and
McCormick [1957]. During anesthesia, mice were grasped
firmly by the loose skin behind the head. A hypodermic
needle (0.4 mm external diameter) attached to a 10 m l sy-
ringe was inserted perpendicularly through the skull and
no more than 2 mm into the brain of the mouse, where 5 m l
of solution was administered. The injection site was 1 mm
to the right or left from the midpoint on a line drawn through
to the anterior base of the ears. Injections were performed
randomly into the right or left ventricle. To ascertain that
the drugs were administered exactly into the cerebral ven-
tricle, some mice were injected with 5 m l of diluted 1:10
India ink and their brains examined macroscopically after
sectioning. The accuracy of the injection technique was
evaluated, with 95% of injections being correct.
Reagents and Compounds
The following compounds were used: AG-4 (2-me-
thyl-5-N,N-dimethylaminomethyl-cyclopentan-1-one
methyl iodide) was a kind gift of Prof. Giannella (Univer-
sity of Camerino); diphenhydramine hydrochloride (De
Angeli); mecamylamine hydrochloride, clonidine hydro-
chloride (RBI, Natick, MA), nicotine dihydrogentartrate,
dihydro- b -erythroidine (Fluka, Buchs, Switzerland);
baclofen, piracetam, physostigmine hemisulphate, sco-
polamine hydrobromide (Sigma, St. Louis, MO).
Drugs were dissolved in isotonic (NaCl 0.9%) sa-
line solution and concentrations were prepared in such
a way that the necessary dose could be administered in
a volume of 5 m l per mouse by icv injection and 10 ml
kg–1 by ip injection
Statistical Analysis
All experimental results are given as the mean –  SEM.
ANOVA, followed by Fisher’s Protected Least Significant
Difference procedure for post-hoc comparison, were used
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to verify significance between two means. Data were ana-
lyzed with the StatView software for the Macintosh (1992).
P-values of less than 0.05 were considered significant.
RESULTS
Antiamnesic Activity of AG-4
The nicotinic agonist AG-4 prevented amnesia in-
duced by the antimuscarinic drug scopolamine (1.5 mg
kg–1 ip) in the mouse passive avoidance test (Fig. 1). AG-
4, at the doses of 10 and 25 m g per mouse icv, was com-
pletely ineffective, whereas at the dose of 100 m g per
mouse icv it prevented antimuscarinic amnesia, reach-
ing entrance latency values comparable to those produced
by saline-treated mice.
The antiamnesic effect of AG-4 was also equal to
that produced by nicotine (2 mg kg–1 ip) and the well-
known nootropic drug piracetam (30 mg kg–1 ip) (Fig. 1).
However, at the active dose, AG-4 did not enhance the
entrance latency in unamnesic mice in comparison with
the control group (Fig. 1). There were no differences ob-
served in the various entrance latencies of every group in
the training session of the passive avoidance test ( Fig. 1).
The administration of AG-4, at the dose of 100 m g
per mouse icv, antagonized also the memory disruption
produced by the two nicotinic antagonists: mecamy-
lamine (20 mg kg–1 ip; Fig. 2) and dihydro- b -erythroi-
dine (10 m g per mouse icv; Fig. 3). The antiamnesic effect
of AG-4 was comparable to that exerted by nicotine (2–5
mg kg–1 ip; Figs. 2, 3), by the anticholinesterase inhibitor
physostigmine (0.2 mg kg–1 ip; Fig. 2) and by the nootropic
drug piracetam (30 mg kg–1 ip; Fig. 3).
AG-4, at the dose of 100 m g per mouse icv, was able
to prevent amnesia induced by the a 2 agonist clonidine
(0.125 mg kg–1 ip), the GABAB agonist baclofen (2 mg kg
–
1 ip) and the H1 antagonist diphenhydramine (20 mg kg
–
1 ip) (Fig. 4) in the mouse passive avoidance test. This
antiamnesic effect was comparable to that exerted by
piracetam (30 mg kg–1 ip; Fig. 4).
Effect of AG-4 on Mouse Rota-Rod Test and
Mouse Animex Apparatus
It should be noted that AG-4 elicited its modulatory
effect on cognitive processes without changing either gross
behavior or motor coordination and spontaneous motility
Fig. 1. Dose–response curve of AG-4 in comparison with piracetam and
nicotine on amnesia induced by scopolamine (1.5 mg kg–1 ip) in the mouse
passive avoidance test. AG-4 (icv), piracetam (icv), and nicotine (icv) were
administered 20 min before the training session, while scopolamine was
injected immediately afterwards. The number of mice is inside the col-
umn. *P < 0.01 in comparison with scopolamine-treated mice.
Fig. 2. Dose–response curve of AG-4 in comparison with nicotine and
physostigmine on amnesia induced by mecamylamine (20 mg kg–1 ip) in the
mouse passive avoidance test. AG-4 (icv), nicotine (icv), and physostigmine
(icv) were administered 20 min before the training session, while mecamy-
lamine was injected immediately afterwards. The number of mice is inside
the column. *P < 0.01 in comparison with mecamylamine-treated mice.
Fig. 3. Dose–response curve of AG-4 in comparison with nicotine and
piracetam on amnesia induced by dihydro-b -erythroidine (10 m g per
mouse icv) in the mouse passive avoidance test. AG-4 (icv), nicotine (icv),
and piracetam (icv) were administered 20 min before the training ses-
sion, while dihydro- b -erythroidine was injected immediately afterwards.
The number of mice is inside the column. *P < 0.01 in comparison with
dihydro- b -erythroidine-treated mice.
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as revealed, respectively, by the mouse Rota-rod test
(Table 1) and the rat Animex apparatus (Fig. 5). AG-4,
administered at the active dose, did not reduce the en-
durance time on the rotating rod in comparison with sa-
line-treated mice (Table 1).The spontaneous motility of
mice was unmodified by AG-4 administration (100 m g
per mouse icv) as revealed by the Animex apparatus in
comparison with saline-treated rats (Fig. 5).
DISCUSSION
The present results describe acute effects observed
with AG-4 on experimentally impaired memory in mice.
AG-4 has been demonstrated to prevent amnesia induced
by pharmacological treatments in the passive avoidance test.
That stimulation of the nicotinic system improves
cognitive processes has long been observed (see Intro-
duction). On the other hand, the administration of nico-
tinic ACh receptor antagonists, such as mecamylamine,
produces a dose-dependent impairment of performance
in the passive avoidance test [Elrod and Buccafusco,
1991]. The administration of scopolamine, an unselec-
tive muscarinic ACh receptor antagonist, results in im-
paired learning and memory in humans [Frumier et al.,
1976] and animals [Dilts and Berry, 1967; Levin and
Bowman, 1986].
Amnesia can also be obtained by modulating neu-
rotransmitter systems different other than the cholin-
ergic. GABA is the main inhibitory neurotransmitter
in the brain and it plays an important role in learning
and memory. The activation of GABAA receptors im-
pairs memory performances [Jerusalinsky et al., 1994]
and the stimulation of GABAB receptors by baclofen
disrupts memory after systemic, intra-amygdala or
intraseptal administration [Swartzwelder et al., 1987;
Castellano et al., 1989; Stackman and Walsh, 1994]. The
antihistaminics are known to exert a variety of effects
on the central nervous system. Central depression usu-
ally accompanies therapeutic doses of the H1 antago-
nists, which appears to be related to occupancy of
cerebral H1 receptors; impairment of cognitive func-
tions is a common manifestation [Simons and Simons,
1994]. Furthermore, the administration of the cerebral
H1 antagonist diphenhydramine induces amnesia also
in animals [Kamei et al., 1990; Galeotti et al., 1998]. It
has also been reported that activation of a 2 receptors
modulates memory processes. The administration of the
a 2 receptor agonist clonidine induces amnesia [Laza-
rova-Bakarova et al., 1991; Varonina et al., 1991; Gen-
kova-Papazova et al., 1997].
AG-4 was able to prevent amnesia induced by the
administration of scopolamine, mecamylamine, b -eryth-
Fig. 4. Dose–response curve of AG-4 in comparison with piracetam
on amnesia induced in the mouse by clonidine (0.125 mg kg –1 ip),
baclofen (2 mg kg –1 ip), and diphenhydramine (20 mg kg –1 ip) in the
passive avoidance test. AG-4 (icv) and piracetam (icv) were adminis-
tered 20 min before the training session, clonidine 60 min before,
baclofen and diphenhydramine immediately afterwards. Each column
represents the mean of at least 10 mice. *P < 0.01 in comparison with
amnesic drug-treated animals.
TABLE 1. Effect of AG-4 in Comparison With Nicotine in the Mouse
Roda- Test
Endurance time on Rota-rod (s)
Before After treatment
treatment 15 min 30 min 45 min
Saline 96.5 ± 7.2 91.2 ± 7.9 102.3 ± 8.6 95.4 ± 7.6
icv (10) (10) (10) (10)
AG-4 96.8 ± 7.2 88.9 ± 6.7 94.7 ± 9.2 89.5 ± 8.3
100 m g icv (9) (9) (9) (9)
Nicotine 98.7 ± 8.2  63.5 ± 8.1* 75.4 ± 0.1** 94.3 ± 8.8
10 m g icv (8) (8) (8) (8)
**P < 0.05; *P < 0.01 in comparison with the corresponding saline
controls. The number of mice is shown in parentheses.
Fig. 5. Lack of effect of AG-4 on mouse spontaneous motility. Each
column represents the mean of 15 mice.
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roidine, clonidine, baclofen, and diphenhydramine. Thus,
AG-4 counteracts amnesia not only induced by nicotinic
antagonists, but also that obtained independently from a
nicotinic blockade.
AG-4 is also endowed with antinociceptive prop-
erties and the time course of the antiamnesic activity of
AG-4 was equal to that observed for its antinociceptive
action, reaching its maximum between 15 and 30 min
after injection [Ghelardini et al., 1997]. Therefore, in the
learning and memory experiments AG-4 was adminis-
tered 20 min before the training session.
The evaluation of the behavioral parameters in mice
indicates that AG-4 exerted its antiamnesic activity with-
out producing any behavioral side effect. AG-4, at the
active dose, nor did impair motor coordination as revealed
by the Rota-rod test or modify spontaneous motility, as
indicated by the Animex apparatus. Therefore, AG-4
shares many of the positive CNS attributes (e.g., memory-
enhancing action, antinociception) of nicotine, but exhib-
its a reduced propensity to elicit the typical side effects,
such as tremors, increase of spontaneous motility pro-
duced by injection of nicotine, a limit for its potential
use as a safe treatment of cognitive dysfunctions. In other
words, AG-4 is able to counteract amnesia in a physi-
ological manner.
In summary, AG-4 appears to have cognitive-en-
hancing properties in the presence of pharmacologically
induced amnesia. On these bases, AG-4 could be con-
sidered a new potential antiamnesic drug useful in the
treatment of cognitive disorders.
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